Icelanders' DNA Helps Map Disease

Article

REYKJAVIK, Iceland-Pharmaceutical company Hoffman-La Roche will try to develop a schizophrenia drug based on information from the Icelandic gene pool.

A research project done by deCODE genetics in Iceland has been using the entire Icelandic population as a study subject. Kari Stefansson, deCODE CEO, said the majority of the country's 270,000 people have been included in the DNA database.

Roche agreed to pay the company $200 million for information gathered from the country's DNA. Since the deal was signed in February 1998, deCode has found genes related to eight different diseases.

The schizophrenia gene encodes a protein that appears to be involved with the disease itself. Another protein that interacts with the one made by the gene may also provide a target for a drug.

Schizophrenia affects 1% of the global population and usually appears during adolescence or young adulthood. Drugs can currently control hallucinations, delusions, and emotional disturbances caused by the disease.

Information from www.arizonarepublic.com

Recent Videos
Anthony Bondon CRCST, CHL, BSM, AAS, SME, LSSYB
Deannard Esnard, CRCST, CIS, CER, CHL, CFER, CQUIA
Kevin Bush, Jr, DHSc, EdD, MSHA, MA, MS, FACHE
Vatsala Rangachar Srinivasa, MPH
Sarah Vinson, MBA, CRCST
Kevin Anderson, MBA, BS, CRCST, Senior Manager, Commercial Education Services, Heatlthmark, a Getinge Company
Damien Berg, BA, BS, CRCST, AAMIF, is the vice president of strategic initiatives for the HSPA.
Annet Adegboyega, DNP, MSN, BSN, RN, CNOR; Mihyun "Rose" Jang, MSN, MPH, BSN, RN, CNOR; and Renilda Tijones, MSN, BSN, RN, CNOR.
Roundtable of Vet IPs (Adobe Stock)
APIC 2025 President Carol McLay, DrPH, MPH, RN, CIC FAPIC   (Image credit: APIC)
Related Content